News | Remote Monitoring | September 21, 2015

Zoll Acquires Heart Failure Monitoring Company Kyma Medical Technologies

Kyma's µ-Cor System for remote fluid monitoring will complement the Zoll LifeVest for heart failure

Zoll, acquires, Kyma Medical Technologies, LifeVest, µ-Cor System, heart failure, remote monitoring

µ-Cor System image courtesy of Kyma Medical Technologies

September 21, 2015 — Zoll Medical Corp. announced that it has acquired Tel Aviv, Israel-based Kyma Medical Technologies Ltd., which develops technologies to measure early signs of congestive heart failure.

Currently, Kyma is developing a remote patient monitoring system for fluid management in a variety of patients including those suffering from heart failure. This µ-Cor System uses radio frequency-based technology to monitor the level of fluid in the lungs. It also collects data on heart rate, respiration rate, activity and posture, all of which are analyzed using proprietary algorithms to determine patient-specific vital signs trends. Once a potential deterioration in the patient’s condition is identified, a notification is sent to the patient’s medical team.

“The acquisition of Kyma Medical will allow Zoll to broaden its product offerings with additional technologies designed to improve outcomes for heart failure patients with fluid management problems, with the goal of reducing hospitalizations," said Jason T. Whiting, president of Zoll LifeVest. “With the acquisition, Kyma’s technology will be able to better reach global markets through Zoll’s existing network. Additionally, we expect to leverage Kyma’s strong R&D capabilities as well as the broader research talent available in Israel.”

In January 2015, Kyma announced that it had received CE Mark approval for the µ-Cor System for monitoring thoracic fluid content, electrocardiograms (ECG), heart rate, respiration rate, activity and posture.

Zoll plans to maintain Kyma’s facilities and workforce in Israel and California as a part of Zoll’s LifeVest division.

For more information: www.zoll.com

Related Content

Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
Overlay Init